{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-243413","form_type":"8-K","ticker":"IDYA","cik":"0001676725","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2024-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.195739+00:00","generated_at":"2026-05-30T10:04:51.755564+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"IDEAYA reports 33% ORR in Phase 1 IDE397 in MTAP-deletion urothelial cancer and NSCLC","bullets":["Overall response rate 33% (1 CR, 8 PR) in 27 evaluable patients; all 9 responses confirmed.","Confirmed ORR by tumor: 40% (4/10) urothelial, 38% (3/8) squamous NSCLC, 22% (2/9) adenocarcinoma NSCLC.","Disease control rate 93%; median treatment duration >6.2 months; 15 of 27 patients still on treatment.","ctDNA molecular response rate 81% (≥50% reduction) and 33% (≥90% reduction) in 21 reportable patients.","Favorable safety: 18% Grade 3+ drug-related AEs; no drug-related SAEs or discontinuations; IDE397 + Trodelvy combo to start Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-243413","json":"https://secwatch.observer/filing/0001193125-24-243413.json","markdown":"https://secwatch.observer/filing/0001193125-24-243413.md","text":"https://secwatch.observer/filing/0001193125-24-243413.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000119312524243413/0001193125-24-243413-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000119312524243413/d898951d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T10:04:51.755564+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}